Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

Popular nasal decongestant doesn’t relieve congestion, FDA experts say

Por: Portland Press Herald World September 12, 2023

thumbnail

Sudafed and other common nasal decongestants containing pseudoephedrine are on display behind the counter at Hospital Discount Pharmacy in Edmond, Okla., Jan. 11, 2005. AP Photo, File WASHINGTON — The leading decongestant used by millions of Americans looking for relief from a stuffy nose is likely no better than a dummy pill, according to government experts who reviewed the latest research on the long-questioned drug ingredient. Advisers to... + full article



Similar News

Popular nasal decongestant doesn't actually relieve congestion, FDA experts say

Los Angeles Times USA Science September 12, 2023

thumbnailThe leading decongestant used by millions of Americans looking for relief from a stuffy nose is likely no better than a dummy pill, according to government experts who reviewed the latest research on the long-questioned drug ingredient. Advisors to the Food and Drug... + más

Did Martha Washington really name a cat after Alexander Hamilton? | The Boston Globe

Nasal decongestant phenylephrine, found in many over-the-counter cold and allergy medicines, doesn't work, FDA experts say | CBS News


Mondaire Jones hammered for past congestion pricing support as he seeks seat in car-reliant district

New York Post USA Nation July 16, 2023

thumbnailEx-Rep. Mondaire Jones’ endorsement of congestion pricing to enter and leave Manhattan’s midtown business district could haunt his comeback bid. in Rockland/Hudson Valley’s 17tth congressional district — where there’s stiff opposition from drivers paying significantly... + más

High school scores and top performers from Friday, March 24 | Orlando Sentinel

High school scores and top performers from Tuesday, March 28 | Orlando Sentinel


FDA approves over-the-counter Narcan for opioid OD reversal

New York Post USA Life March 29, 2023

thumbnailOn Wednesday, the Food and Drug Administration approved the first over-the-counter nasal spray that rapidly reverses the effects of an opioid overdose. Narcan, a 4-milligram naloxone hydrochloride nasal spray, will not require a prescription and will be available in... + más

FDA approves first over-the-counter Narcan | Politico

F.D.A. Approves Narcan for Over-the-Counter Sales | The New York Times


FDA panel to reevaluate the most common over-the-counter decongestant, phenylephrine, criticized as useless

CBS News USA Politics March 06, 2023

thumbnailThe Food and Drug Administration plans to ask a panel of its outside advisers to reconsider whether the available , phenylephrine, is effective. There has been a renewed petition to pull it from store shelves over studies showing it was no more effective than a placebo in pills... + más

What Are the Duties of A Trustee? | Forbes

An ingredient in common cold medicines may not actually relieve congestion | WPTV


An ingredient in common cold medicines may not actually relieve congestion

WPTV USA Nation January 12, 2023

thumbnailThere's growing evidence that an ingredient in many cold medicines isn't relieving congestion.Phenylephrine has been proven to be safe, but at least four studies have found that it's not effective in relieving congestion.Jonathan Bernstein, a researcher at the... + más

Congestion pricing killing NYC’s iconic yellow cabs: ‘This is the final nail in the coffin’ | New York Post

Lee Zeldin hits Kathy Hochul on congestion tolls, subway crime at track-push stop | New York Post


Without a nasal vaccine, the U.S. edge in fighting Covid is on the line

Politico USA Health October 15, 2022

thumbnailBiden administration officials are raising concerns that the slow pace of developing a nasal vaccine for Covid-19 in the U.S. could pose a security risk as China, Iran and Russia approve their own vaccines taken through the nose or mouth. Though nasal and oral vaccines are being... + más

Nasal COVID vaccine blows clinical trial, flinging researchers back to the lab | Ars Technica

Nasal COVID vaccine fails to offer desired protection in testing | The Hill


Nasal COVID vaccine blows clinical trial, flinging researchers back to the lab

Ars Technica USA Science October 12, 2022

thumbnailNavigate Filter by topic Settings Front page layout Site theme Comment activity Sign up or login to join the discussions! Sign up to comment and more - Oct 12, 2022 5:17 pm UTC / A man receives an H1N1 nasal flu spray vaccine at an urgent care center on October 16, 2009, in Lake... + más

Nasal COVID vaccine fails to offer desired protection in testing | The Hill

Fintech Company Greenphire Wants To Make Clinical Trials More Representative Of Every Person, From All Backgrounds And Abilities | Forbes



About iurex | Privacy Policy | Disclaimer |